siRNA Genome Screening Approaches to Therapeutic Drug Repositioning

Bridging high-throughput screening (HTS) with RNA interference (RNAi) has allowed for rapid discovery of the molecular basis of many diseases, and identification of potential pathways for developing safe and effective treatments. These features have identified new host gene targets for existing drugs paving the pathway for therapeutic drug repositioning. Using RNAi to discover and help validate new drug targets has also provided a means to filter and prioritize promising therapeutics. This review summarizes these approaches across a spectrum of methods and targets in the host response to pathogens. Particular attention is given to the utility of drug repurposing utilizing the promiscuous nature of some drugs that affect multiple molecules or pathways, and how these biological pathways can be targeted to regulate disease outcome.

[1]  D. Mccormick Sequence the Human Genome , 1986, Bio/Technology.

[2]  M. Curcio,et al.  Silencing cytokeratin 18 gene inhibits intracellular replication of Trypanosoma cruzi in HeLa cells but not binding and invasion of trypanosomes , 2008, BMC Cell Biology.

[3]  M A Fischl,et al.  The efficacy of azidothymidine (AZT) in the treatment of patients with AIDS and AIDS-related complex. A double-blind, placebo-controlled trial. , 1987, The New England journal of medicine.

[4]  J. Schuchhardt,et al.  A Loss-of-Function Screen Reveals Ras- and Raf-Independent MEK-ERK Signaling During Chlamydia trachomatis Infection , 2010, Science Signaling.

[5]  P. Zamore,et al.  Small silencing RNAs: an expanding universe , 2009, Nature Reviews Genetics.

[6]  D. Kalman,et al.  RNAi Screen Reveals an Abl Kinase-Dependent Host Cell Pathway Involved in Pseudomonas aeruginosa Internalization , 2008, PLoS pathogens.

[7]  Chi V Dang,et al.  MYC on the Path to Cancer , 2012, Cell.

[8]  J. Northrop,et al.  Lipofection: a highly efficient, lipid-mediated DNA-transfection procedure. , 1987, Proceedings of the National Academy of Sciences of the United States of America.

[9]  T. Tuschl,et al.  Duplexes of 21-nucleotide RNAs mediate RNA interference in cultured mammalian cells , 2001, Nature.

[10]  John P. Sullivan,et al.  Screensaver: an open source lab information management system (LIMS) for high throughput screening facilities , 2010, BMC Bioinformatics.

[11]  S. Pratap,et al.  Silencing of the Laminin γ-1 Gene Blocks Trypanosoma cruzi Infection , 2006, Infection and Immunity.

[12]  N. Perrimon,et al.  Genome-wide RNAi screen reveals a specific sensitivity of IRES-containing RNA viruses to host translation inhibition. , 2005, Genes & development.

[13]  Aaron N. Chang,et al.  Functional genomics identifies therapeutic targets for MYC-driven cancer , 2012, Proceedings of the National Academy of Sciences.

[14]  Norbert Perrimon,et al.  RNAi screening: new approaches, understandings, and organisms , 2012, Wiley interdisciplinary reviews. RNA.

[15]  E. Lai Micro RNAs are complementary to 3′ UTR sequence motifs that mediate negative post-transcriptional regulation , 2002, Nature Genetics.

[16]  J. Huggins Prospects for treatment of viral hemorrhagic fevers with ribavirin, a broad-spectrum antiviral drug. , 1989, Reviews of infectious diseases.

[17]  E. Sontheimer,et al.  Origins and Mechanisms of miRNAs and siRNAs , 2009, Cell.

[18]  Robert S. Pinals,et al.  A double‐blind, placebo‐controlled trial , 1986 .

[19]  T. Chertemps,et al.  Anopheles Gambiae PRS1 Modulates Plasmodium Development at Both Midgut and Salivary Gland Steps , 2010, PloS one.

[20]  Chris Sander,et al.  Cellular cofactors affecting hepatitis C virus infection and replication , 2007, Proceedings of the National Academy of Sciences.

[21]  N. Hacohen,et al.  A Physical and Regulatory Map of Host-Influenza Interactions Reveals Pathways in H1N1 Infection , 2009, Cell.

[22]  Mohsen Khorshid,et al.  PAR-CliP - A Method to Identify Transcriptome-wide the Binding Sites of RNA Binding Proteins , 2010, Journal of visualized experiments : JoVE.

[23]  T. Rana,et al.  RNAi in human cells: basic structural and functional features of small interfering RNA. , 2002, Molecular cell.

[24]  R. W. Hansen,et al.  The price of innovation: new estimates of drug development costs. , 2003, Journal of health economics.

[25]  M. Bukrinsky,et al.  Active nuclear import of human immunodeficiency virus type 1 preintegration complexes. , 1992, Proceedings of the National Academy of Sciences of the United States of America.

[26]  Lucas Pelkmans,et al.  RNAi screening reveals proteasome- and Cullin3-dependent stages in vaccinia virus infection. , 2012, Cell reports.

[27]  C. Burge,et al.  Most mammalian mRNAs are conserved targets of microRNAs. , 2008, Genome research.

[28]  A. Fire,et al.  Potent and specific genetic interference by double-stranded RNA in Caenorhabditis elegans , 1998, Nature.

[29]  Nir Hacohen,et al.  Novel HIV-1 Knockdown Targets Identified by an Enriched Kinases/Phosphatases shRNA Library Using a Long-Term Iterative Screen in Jurkat T-Cells , 2010, PloS one.

[30]  T. Ashburn,et al.  Drug repositioning: identifying and developing new uses for existing drugs , 2004, Nature Reviews Drug Discovery.

[31]  Daniel Becker,et al.  Genome-wide RNAi screen identifies human host factors crucial for influenza virus replication , 2010, Nature.

[32]  K. Hartshorn,et al.  Novel strategies for prevention and treatment of influenza , 2005, Expert opinion on therapeutic targets.

[33]  Sonali Patil,et al.  Getting Started in Biological Pathway Construction and Analysis , 2008, PLoS Comput. Biol..

[34]  David S. Wishart,et al.  DrugBank: a knowledgebase for drugs, drug actions and drug targets , 2007, Nucleic Acids Res..

[35]  P. Whittaker,et al.  RNA interference: From gene silencing to gene-specific therapeutics , 2005, Pharmacology & Therapeutics.

[36]  R. Tripp,et al.  Targeting Organic Anion Transporter 3 with Probenecid as a Novel Anti-Influenza A Virus Strategy , 2012, Antimicrobial Agents and Chemotherapy.

[37]  Brad T. Sherman,et al.  Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources , 2008, Nature Protocols.

[38]  Reuven Agami,et al.  A large-scale RNAi screen in human cells identifies new components of the p53 pathway , 2004, Nature.

[39]  Christian von Mering,et al.  Rnai Screen of Salmonella Invasion Shows Role of Copi in Membrane Targeting of Cholesterol and Cdc42 , 2022 .

[40]  B. Tümmler,et al.  Caenorhabditis elegans Semi-Automated Liquid Screen Reveals a Specialized Role for the Chemotaxis Gene cheB2 in Pseudomonas aeruginosa Virulence , 2009, PLoS pathogens.

[41]  G. Friedland,et al.  Pharmacokinetics and whole-blood bactericidal activity against Mycobacterium tuberculosis of single doses of PNU-100480 in healthy volunteers. , 2010, The Journal of infectious diseases.

[42]  Rebecca A. Bozym,et al.  Comparative RNAi screening reveals host factors involved in enterovirus infection of polarized endothelial monolayers. , 2011, Cell host & microbe.

[43]  C. Conrad,et al.  Automated microscopy for high-content RNAi screening , 2010, The Journal of cell biology.

[44]  Yingyuan Mo MicroRNA regulatory networks and human disease , 2012, Cellular and Molecular Life Sciences.

[45]  C. Echeverri,et al.  Host scavenger receptor SR-BI plays a dual role in the establishment of malaria parasite liver infection. , 2008, Cell host & microbe.

[46]  V. Kim,et al.  Biogenesis of small RNAs in animals , 2009, Nature Reviews Molecular Cell Biology.

[47]  L. Lim,et al.  Widespread siRNA "off-target" transcript silencing mediated by seed region sequence complementarity. , 2006, RNA.

[48]  Norbert Perrimon,et al.  Genome-Wide RNAi Screen for Host Factors Required for Intracellular Bacterial Infection , 2005, Science.

[49]  A. Reynolds,et al.  Rational siRNA design for RNA interference , 2004, Nature Biotechnology.

[50]  J. Rossi,et al.  Silencing of Gene Expression in Cultured Cells Using Small Interfering RNAs , 2010, Current protocols in cell biology.

[51]  Norbert Perrimon,et al.  Drosophila RNAi Screen Reveals CD36 Family Member Required for Mycobacterial Infection , 2005, Science.

[52]  S. Raja,et al.  Sildenafil: emerging cardiovascular indications. , 2004, The Annals of thoracic surgery.

[53]  M. Newton,et al.  Drosophila RNAi screen identifies host genes important for influenza virus replication , 2008, Nature.

[54]  H. Hermeking,et al.  The MYC oncogene as a cancer drug target. , 2003, Current cancer drug targets.

[55]  P. Nde,et al.  Stable RNA interference of host thrombospondin‐1 blocks Trypanosoma cruzi infection , 2006, FEBS letters.

[56]  B. Li,et al.  Expression profiling reveals off-target gene regulation by RNAi , 2003, Nature Biotechnology.

[57]  N. Heaton,et al.  RNA Interference and Single Particle Tracking Analysis of Hepatitis C Virus Endocytosis , 2009, PLoS pathogens.

[58]  J. Wolff,et al.  siRNA and DNA transfer to cultured cells. , 2009, Methods in molecular biology.

[59]  M. Garcia-Blanco,et al.  Discovery of Insect and Human Dengue Virus Host Factors , 2009, Nature.

[60]  R. Valdivia,et al.  Human Genome-Wide RNAi Screen for Host Factors That Modulate Intracellular Salmonella Growth , 2012, PloS one.

[61]  K. Heeg,et al.  Modifications in Small Interfering RNA That Separate Immunostimulation from RNA Interference1 , 2008, The Journal of Immunology.

[62]  John P. Overington,et al.  How many drug targets are there? , 2006, Nature Reviews Drug Discovery.

[63]  Nathan F. Bouxsein,et al.  Cationic liposome-nucleic acid complexes for gene delivery and silencing: pathways and mechanisms for plasmid DNA and siRNA. , 2010, Topics in current chemistry.

[64]  Y. Takakura,et al.  Nonviral vector-mediated RNA interference: its gene silencing characteristics and important factors to achieve RNAi-based gene therapy. , 2009, Advanced drug delivery reviews.

[65]  B. Reinhart,et al.  The 21-nucleotide let-7 RNA regulates developmental timing in Caenorhabditis elegans , 2000, Nature.

[66]  L. Shulman Genome-wide siRNA screen identifies SMCX, EP400, and Brd4 as E2-dependent regulators of human papillomavirus oncogene expression , 2010 .

[67]  A. Miller,et al.  Gene transfer by retrovirus vectors occurs only in cells that are actively replicating at the time of infection , 1990, Molecular and cellular biology.

[68]  Ruth R. Montgomery,et al.  RNA interference screen for human genes associated with West Nile virus infection , 2008, Nature.

[69]  Joshua N Leonard,et al.  HIV evades RNA interference directed at TAR by an indirect compensatory mechanism. , 2008, Cell host & microbe.

[70]  Russell G. Jones,et al.  A Kinome RNAi Screen Identified AMPK as Promoting Poxvirus Entry through the Control of Actin Dynamics , 2010, PLoS pathogens.

[71]  Serge Batalov,et al.  Identification of modulators of TRAIL-induced apoptosis via RNAi-based phenotypic screening. , 2003, Molecular cell.

[72]  M. Bray,et al.  Current and future antiviral therapy of severe seasonal and avian influenza , 2008, Antiviral Research.

[73]  Bruce J. Aronow,et al.  ToppCluster: a multiple gene list feature analyzer for comparative enrichment clustering and network-based dissection of biological systems , 2010, Nucleic Acids Res..

[74]  Anindya Dutta,et al.  Small RNAs with Imperfect Match to Endogenous mRNA Repress Translation , 2003, Journal of Biological Chemistry.

[75]  S. Wright,et al.  Kinetics of interactions of para-aminohippurate, probenecid, cysteine conjugates and N-acetyl cysteine conjugates with basolateral organic anion transporter in isolated rabbit proximal renal tubules. , 1995, The Journal of pharmacology and experimental therapeutics.

[76]  A new Houdini act: multiple routes for HIV-1 escape from RNAi-mediated inhibition. , 2009, Future microbiology.

[77]  N. Yokoyama,et al.  DBR1 siRNA inhibition of HIV-1 replication , 2005, Retrovirology.

[78]  Raymond Lo,et al.  Raloxifene attenuates Pseudomonas aeruginosa pyocyanin production and virulence. , 2012, International journal of antimicrobial agents.

[79]  M. Goldenberg,et al.  Safety and efficacy of sildenafil citrate in the treatment of male erectile dysfunction. , 1998, Clinical therapeutics.

[80]  J. O'donnell,et al.  Emerging therapies in the long‐term management of hyperuricaemia and gout , 2007, Internal medicine journal.

[81]  Ajit S. Narang,et al.  Subcellular Fate and Off-Target Effects of siRNA, shRNA, and miRNA , 2011, Pharmaceutical Research.

[82]  P. Ward,et al.  The anti-influenza drug oseltamivir exhibits low potential to induce pharmacokinetic drug interactions via renal secretion-correlation of in vivo and in vitro studies. , 2002, Drug metabolism and disposition: the biological fate of chemicals.

[83]  M. Emerman,et al.  Human immunodeficiency virus infection of cells arrested in the cell cycle. , 1992, The EMBO journal.

[84]  K. Hanley,et al.  RNA interference modulates replication of dengue virus in Drosophila melanogaster cells , 2010, BMC Microbiology.

[85]  R. Davey,et al.  Pharmacokinetics and Tolerability of Oseltamivir Combined with Probenecid , 2008, Antimicrobial Agents and Chemotherapy.

[86]  Anastasia Khvorova,et al.  Induction of the interferon response by siRNA is cell type- and duplex length-dependent. , 2006, RNA.

[87]  F. Recillas-Targa Multiple strategies for gene transfer, expression, knockdown, and chromatin influence in mammalian cell lines and transgenic animals , 2006, Molecular biotechnology.

[88]  Andrew Simon Bell,et al.  Sildenafil (VIAGRATM), a potent and selective inhibitor of type 5 cGMP phosphodiesterase with utility for the treatment of male erectile dysfunction , 1996 .

[89]  S. Eddy Non–coding RNA genes and the modern RNA world , 2001, Nature Reviews Genetics.

[90]  H. Agaisse,et al.  RNAi Screen in Drosophila Cells Reveals the Involvement of the Tom Complex in Chlamydia Infection , 2007, PLoS pathogens.

[91]  A. MacNeil,et al.  Ebola and Marburg Hemorrhagic Fevers: Neglected Tropical Diseases? , 2012, PLoS neglected tropical diseases.

[92]  A. Kolokoltsov,et al.  Identification of novel cellular targets for therapeutic intervention against Ebola virus infection by siRNA screening , 2009, Drug development research.

[93]  P. Boag,et al.  Comparative high-throughput RNAi screening methodologies in C. elegans and mammalian cells. , 2012, New biotechnology.

[94]  J. Chu,et al.  Small interference RNA profiling reveals the essential role of human membrane trafficking genes in mediating the infectious entry of dengue virus , 2010, Virology Journal.

[95]  Dhiraj Kumar,et al.  Identification of Host-Dependent Survival Factors for Intracellular Mycobacterium tuberculosis through an siRNA Screen , 2010, PLoS pathogens.

[96]  Ruili Huang,et al.  The NCGC Pharmaceutical Collection: A Comprehensive Resource of Clinically Approved Drugs Enabling Repurposing and Chemical Genomics , 2011, Science Translational Medicine.

[97]  Ronald Gieschke,et al.  Population Pharmacokinetics of Oseltamivir When Coadministered With Probenecid , 2008, Journal of clinical pharmacology.

[98]  M. Emerman,et al.  Passage through mitosis is required for oncoretroviruses but not for the human immunodeficiency virus , 1994, Journal of virology.

[99]  Q. Lu,et al.  Genome-Wide RNAi Screen in \(IFN-\gamma-Treated\) Human Macrophages Identifies Genes Mediating Resistance to the Intracellular Pathogen Francisella tularensis , 2012 .

[100]  H. Agaisse,et al.  RNAi Screen Reveals Host Cell Kinases Specifically Involved in Listeria monocytogenes Spread from Cell to Cell , 2011, PloS one.

[101]  C. Bakal,et al.  Genomic screening with RNAi: results and challenges. , 2010, Annual review of biochemistry.

[102]  Tyson A. Clark,et al.  HITS-CLIP yields genome-wide insights into brain alternative RNA processing , 2008, Nature.

[103]  B. Berkhout,et al.  Inhibition of HIV-1 replication with stable RNAi-mediated knockdown of autophagy factors , 2012, Virology Journal.

[104]  C. Chong,et al.  New uses for old drugs , 2007, Nature.

[105]  C. Echeverri,et al.  High-throughput RNA interference strategies for target discovery and validation by using synthetic short interfering RNAs: functional genomics investigations of biological pathways. , 2005, Methods in enzymology.

[106]  Yi Zhao,et al.  NONCODE: an integrated knowledge database of non-coding RNAs , 2004, Nucleic Acids Res..

[107]  M. Kay,et al.  Adeno-associated virus vectors for short hairpin RNA expression. , 2005, Methods in enzymology.

[108]  P. Schultz,et al.  Identification of Human Kinases Involved in Hepatitis C Virus Replication by Small Interference RNA Library Screening* , 2008, Journal of Biological Chemistry.

[109]  Philip E. Bourne,et al.  PROMISCUOUS: a database for network-based drug-repositioning , 2010, Nucleic Acids Res..

[110]  Raymond T Chung,et al.  A functional genomic screen identifies cellular cofactors of hepatitis C virus replication. , 2009, Cell host & microbe.

[111]  Michael Peyton,et al.  Synthetic lethal screen identification of chemosensitizer loci in cancer cells , 2007, Nature.

[112]  H. Himmelbauer,et al.  An endoribonuclease-prepared siRNA screen in human cells identifies genes essential for cell division , 2004, Nature.

[113]  J. Lieberman,et al.  Identification of Host Proteins Required for HIV Infection Through a Functional Genomic Screen , 2007, Science.

[114]  V. Ambros,et al.  The C. elegans heterochronic gene lin-4 encodes small RNAs with antisense complementarity to lin-14 , 1993, Cell.

[115]  Joanne Odenkirchen,et al.  National Institute of Neurological Disorders and Stroke Common Data Element Project – approach and methods , 2012, Clinical trials.

[116]  S. Broder,et al.  Development of antiretroviral therapy for the acquired immunodeficiency syndrome and related disorders. A progress report. , 1987, The New England journal of medicine.

[117]  Jijing Luo,et al.  Functional Analysis of Host Factors that Mediate the Intracellular Lifestyle of Cryptococcus neoformans , 2011, PLoS pathogens.

[118]  J. Beigel,et al.  ANTIVIRAL COMPOUNDS IN THE PIPELINE TO TACKLE H1N1 INFLUENZA INFECTION. , 2010, Drugs of the future.

[119]  David Torres,et al.  Scavenger Receptors in Human Airway Epithelial Cells: Role in Response to Double-Stranded RNA , 2012, PloS one.

[120]  Patrick J. Paddison,et al.  A resource for large-scale RNA-interference-based screens in mammals , 2004, Nature.

[121]  T. Rana,et al.  Modulating HIV-1 replication by RNA interference directed against human transcription elongation factor SPT5 , 2004, Retrovirology.

[122]  Li Li,et al.  Computational approaches for microRNA studies: a review , 2010, Mammalian Genome.

[123]  J. Lowen What's in a number? , 2010, Minnesota medicine.

[124]  Stijn van Dongen,et al.  miRBase: tools for microRNA genomics , 2007, Nucleic Acids Res..

[125]  P. O’Farrell,et al.  Identification of Drosophila Gene Products Required for Phagocytosis of Candida albicans , 2005, PLoS biology.

[126]  A. Judge,et al.  2'-O-methyl-modified RNAs act as TLR7 antagonists. , 2007, Molecular therapy : the journal of the American Society of Gene Therapy.

[127]  N. Heaton,et al.  Roles for endocytic trafficking and phosphatidylinositol 4-kinase III alpha in hepatitis C virus replication , 2009, Proceedings of the National Academy of Sciences.

[128]  Bohdan Waszkowycz,et al.  Towards improving compound selection in structure-based virtual screening. , 2008, Drug discovery today.

[129]  P. O’Farrell,et al.  The endocytic pathway mediates cell entry of dsRNA to induce RNAi silencing , 2006, Nature Cell Biology.

[130]  Sarman Singh,et al.  Genome-wide Analysis of the Host Intracellular Network that Regulates Survival of Mycobacterium tuberculosis , 2010, Cell.

[131]  S. Pratap,et al.  Silencing of the laminin gamma-1 gene blocks Trypanosoma cruzi infection. , 2006, Infection and immunity.

[132]  Francis S. Collins,et al.  Mining for therapeutic gold , 2011, Nature Reviews Drug Discovery.

[133]  MISSION esiRNA for RNAi screening in mammalian cells. , 2010, Journal of visualized experiments : JoVE.

[134]  David J. Adams,et al.  The IFITM Proteins Mediate Cellular Resistance to Influenza A H1N1 Virus, West Nile Virus, and Dengue Virus , 2009, Cell.

[135]  Sean Ekins,et al.  In silico repositioning of approved drugs for rare and neglected diseases. , 2011, Drug discovery today.

[136]  Ping Wu,et al.  Role for lysosomal enzyme β-hexosaminidase in the control of mycobacteria infection , 2008, Proceedings of the National Academy of Sciences.

[137]  François Chevenet,et al.  OligoHeatMap (OHM): an online tool to estimate and display hybridizations of oligonucleotides onto DNA sequences , 2008, Nucleic Acids Res..

[138]  G. Hannon,et al.  Inducible, reversible, and stable RNA interference in mammalian cells , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[139]  M. Mhlanga,et al.  Host gene targets for novel influenza therapies elucidated by high‐throughput RNA interference screens , 2012, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[140]  R. Tripp,et al.  MicroRNA Regulation of Human Protease Genes Essential for Influenza Virus Replication , 2012, PloS one.

[141]  B. Schnierle,et al.  Selective gene silencing by viral delivery of short hairpin RNA , 2010, Virology Journal.

[142]  B. Williams,et al.  Detection of foreign RNA: Implications for RNAi , 2005, Immunology and cell biology.

[143]  J. Caldwell,et al.  “UnPAKing” Human Immunodeficiency Virus (HIV) Replication: Using Small Interfering RNA Screening To Identify Novel Cofactors and Elucidate the Role of Group I PAKs in HIV Infection , 2006, Journal of Virology.

[144]  K. Mitani,et al.  Adenovirus as an integrating vector. , 2002, Current gene therapy.

[145]  Malorye Allison,et al.  NCATS launches drug repurposing program , 2012, Nature Biotechnology.

[146]  P. de Figueiredo,et al.  RNAi Screen of Endoplasmic Reticulum–Associated Host Factors Reveals a Role for IRE1α in Supporting Brucella Replication , 2008, PLoS pathogens.

[147]  R. W. Hansen,et al.  Research and development costs for new drugs by therapeutic category. A study of the US pharmaceutical industry. , 1995, PharmacoEconomics.

[148]  Áine McKnight,et al.  A whole genome screen for HIV restriction factors , 2011, Retrovirology.

[149]  D. Kalman,et al.  RNA Interference Screen Identifies Abl Kinase and PDGFR Signaling in Chlamydia trachomatis Entry , 2008, PLoS pathogens.

[150]  Yong-Jun Kwon,et al.  Visual Genome-Wide RNAi Screening to Identify Human Host Factors Required for Trypanosoma cruzi Infection , 2011, PloS one.

[151]  Wolfgang Huber,et al.  Analysis of cell-based RNAi screens , 2006, Genome Biology.

[152]  Amy S. Espeseth,et al.  siRNA Screening of a Targeted Library of DNA Repair Factors in HIV Infection Reveals a Role for Base Excision Repair in HIV Integration , 2011, PloS one.

[153]  Lorenz M Mayr,et al.  Novel trends in high-throughput screening. , 2009, Current opinion in pharmacology.

[154]  D. Bartel MicroRNAs Genomics, Biogenesis, Mechanism, and Function , 2004, Cell.

[155]  Amy S. Espeseth,et al.  Genome-scale RNAi screen for host factors required for HIV replication. , 2008, Cell host & microbe.

[156]  Mark E. Davis,et al.  Effect of siRNA nuclease stability on the in vitro and in vivo kinetics of siRNA‐mediated gene silencing , 2007, Biotechnology and bioengineering.

[157]  M. Arkin,et al.  A high throughput drug screen for Entamoeba histolytica identifies a new lead and target , 2012, Nature Medicine.

[158]  Istvan Ladunga,et al.  RNAi screening reveals requirement for host cell secretory pathway in infection by diverse families of negative-strand RNA viruses , 2011, Proceedings of the National Academy of Sciences.

[159]  John J Rossi,et al.  Interferon induction by siRNAs and ssRNAs synthesized by phage polymerase , 2004, Nature Biotechnology.

[160]  M. Kinch,et al.  The use of Random Homozygous Gene Perturbation to identify novel host-oriented targets for influenza. , 2009, Virology.

[161]  Anthony J Williams,et al.  Public chemical compound databases. , 2008, Current opinion in drug discovery & development.

[162]  C. Kunin,et al.  Susceptibility of Mycobacterium tuberculosis to sulfamethoxazole, trimethoprim and their combination over a 12 year period in Taiwan. , 2012, The Journal of antimicrobial chemotherapy.

[163]  B. Berkhout,et al.  Long-term inhibition of HIV-1 replication with RNA interference against cellular co-factors. , 2011, Antiviral research.

[164]  Claus Christiansen,et al.  Serological biochemical markers of surrogate efficacy and safety as a novel approach to drug repositioning. , 2011, Drug discovery today.

[165]  Alessandro Spina Pharmaceuticals , 2010, European Journal of Risk Regulation.

[166]  R. König,et al.  Human Host Factors Required for Influenza Virus Replication , 2010, Nature.

[167]  S. Lampel,et al.  The druggable genome: an update. , 2005, Drug discovery today.

[168]  Keiji Fukuda,et al.  Mortality associated with influenza and respiratory syncytial virus in the United States. , 2003, JAMA.

[169]  P. Shankar,et al.  Lentiviral delivery of short hairpin RNAs. , 2009, Advanced drug delivery reviews.

[170]  Atul J. Butte,et al.  Ten Years of Pathway Analysis: Current Approaches and Outstanding Challenges , 2012, PLoS Comput. Biol..

[171]  M A Fischl,et al.  The toxicity of azidothymidine (AZT) in the treatment of patients with AIDS and AIDS-related complex. A double-blind, placebo-controlled trial. , 1987, The New England journal of medicine.

[172]  C. Echeverri,et al.  Kinome-Wide RNAi Screen Implicates at Least 5 Host Hepatocyte Kinases in Plasmodium Sporozoite Infection , 2008, PLoS pathogens.

[173]  W. B. Dreitlein,et al.  Zanamivir and oseltamivir: two new options for the treatment and prevention of influenza. , 2001, Clinical therapeutics.